Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
There is no proven adjuvant treatment after curative surgical resection in patients with
cholangiocarcinoma, although previous meta-analysis suggested potential survival benefit of
adjuvant chemotherapy or radiotherapy in patients with lymph node-positive resected
cholangiocarcinoma. Despite of lack of level 1 evidence and no data which regimen is optimal,
adjuvant chemotherapy is widely used in daily practice setting. Based on this background, the
investigators designed the randomized phase 2 trial comparing capecitabine and gemcitabine
plus cisplatin in patients with resected lymph node-positive extrahepatic cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Bundang CHA Hospital Seoul St. Mary's Hospital Severance Hospital